Outcome Terapi Covid-19 pada Pasien yang Mendapatkan Antikoagulan Profilaksis di RSPAL Dr. Ramelan Surabaya Outcome Covid-19 Anticoagulant Prophylaxis in Covid-19 Patients at Dr. Ramelan Naval Center Hospital Surabaya
Main Article Content
Abstract
Complications of thrombotic and hemorrhagic coagulation often occur in Covid-19 patients, so it is advisable to provide anticoagulant therapy, accompanied by monitoring of parameters of coagulation abnormalities, including D-Dimer. This study aims to determine the outcome of therapy for Covid-19 in patients with anticoagulant prophylaxis use in RSPAL Dr. Ramelan Surabaya. This study is a retrospective descriptive study based on medical records of Covid-19 patients from June-August 2021. The sample in this study was subjects aged >18 years who were confirmed positive for Covid-19 based on RT-PCR, with comorbid or without comorbidities, and received anticoagulant therapy. Then, this study did not include subjects who were pregnant or with malignancy/acute conditions. From 134 research samples, it was found that the use of anticoagulants using a single anticoagulant (n=131, 97.76%) was more widely used, with the most frequently used types being enoxaparin (n=68, 50.75%), and heparin (n=48, 35,8%). In conclusion, the recovery percentage in Covid-19 subjects with anticoagulant therapy was 77.61%, and the percentage of mortality was 22,39%.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All rights reserved. This publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording.
References
World Health Organization. 2015. Ageing Revised the Age Standard. Diakses pada 05 Juli 2022, dari https://www.who.int/health-topics/ageing#tab=tab_1
Covid19.go.id. 04 Juli 2022. Peta Sebaran Covid-19 di Indonesia. Diakses pada 05 Juli 2022, dari https://covid19.go.id/peta-sebaran
Bels J.L.M, Van Kuijk S.M.J, Ghossein-Doha C. et al. 2021. Decreased Serial Scores of Severe Organ Failure Assessment are Associated with Survival in Mechanically Ventilated Patients; the Retrospective Maastricht Intensive Cave Covid Cohort.. J Crit Care. 2021;62;38-45. https://doi.org/10.1016/j.jcrc.2020.11.006
Luis OP, Davide C, Gilles M et al,. 2021. Coronavirus Disease 2019-Associated Trombosis and Coagulophaty: Review of the Pathophysiologycal Characteristic and Implications for Antithrombotic Management. Journal of the American Heart Association. Vol.10, No. 3. https://doi.org/10.1161/JAHA.120.019650
Wahid L, Thomas L,. 2021. Anticoagulant Therapy in Patients Hospitalized With Covid-19. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2021.6212
Berger JS, Kunichoff D, Adhikari Sm Ahuja T et al. 2020. Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients with Covid-19. Atherioscler Thromb Vasc Biol. 2020;40(10);2539-47. https://doi.org/10.1161/atvbaha.120.314872
Ikatan Dokter Indonesia. 2020. Rekomendasi IDI Pemberian Antikoagulan Profilaksis pada Paisen Covid-19 yang Dirawat di Rumah Sakit. Jakarta.
Rozenfeld Y, Beam J, Maier H et al. 2020. A Model of Disparities: Risk Factor Associated with Covid-19 Infection. International Journal for Equity in Health https://equityhealthj.biomedcentral.com/articles/10.1186/s12939-020-01242-z#citeas
Kai Liu, Ying Chen, Ruzheng Lin et al,. 2020. Clinical Features of Covdi-19 in Elderly Patients; a Comparison with Young and Middle-aged Patients. J Infect 80(6):e14-e18 https://doi.org/10.1016%2Fj.jinf.2020.03.005
Eduardo F, Manuel F, Marcelo A et al. 2017. SImmune System Dysfunction in the Elderly. Biomedical Science. 89:1 https://doi.org/10.1590/0001-3765201720160487
PDPI, PERKI, PAPDI, PERDATIN, IDAI. 2021. Revisi Protokol Tatalaksana Covid-19. 14 Juli-2021
Jiang L, Li Y, Du H et al. 2021. Effect of Anticoagulant Administration on the Mortality of Hospitalized Patient with Covid-19: An Update Systematic Review and Meta Analysis. Front Med (Lausanne). 20209:698935. https://doi.org/10.3389%2Ffmed.2021.698935
Kumar D, Kaimaparambil V, Chandralekha S, Lalchandani J. Oral Rivaroxaban in the Prophylaxis of COVID-19 Induced Coagulopathy. J Assoc Physicians India. 2022 Feb;70(2):11-12. PMID: 35436816.
Albani F, Sepe L, Fusina F et al. 2020. Thromboprophylaxis with Enoxaparin is Associated with a Lower Death Rate in Patients Hospitalized with SARS-CoV-2 Infection. A Cohort Study. eClinicalMedicine. Vol. 27 https://doi.org/10.1016/j.eclinm.2020.100562
Barnes G, Burnett A, Blumenstein M et al. 2020. Thromboembolism and Anticoagulant Therapy During the Covid-19 Pandemic: Interim Clinical Guidance from the Anticoagulant Forum. Journal of Thrombosis and Thrombolysis. 50, 72-81 https://doi.org/10.1007/s11239-020-02138-z
Miesbach W, Makris M. 2020. Covid-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. SagePub- Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177%2F1076029620938149
Poterucha TJ, Libby P, Goldhaber S. 2017. More than an Anticoagulant: Do Heparins have Direct anti-inflamatory Effects?. Thromb Haemost 2017;117(03):437-444 https://doi.org/10.1160/TH16-08-062
Qian Z, Lu S, Luo X et al. 2021. Mortality and Clinical Interventions in Critically Ill Patient with Coronavirus Disease 2019: a Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021;8:635560 https://doi.org/10.3389%2Ffmed.2021.635560